Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb.
Publication
, Journal Article
Morse, MA
Published in: Curr Opin Mol Ther
December 2005
Medarex and Bristol-Myers Squibb are developing ipilimumab, an immunostimulatory human antibody against cytotoxic T-lymphocyte antigen-4, for the potential combination or monotherapy treatment of melanoma, prostate, breast, renal and other cancers, as well as HIV infection.
Duke Scholars
Published In
Curr Opin Mol Ther
ISSN
1464-8431
Publication Date
December 2005
Volume
7
Issue
6
Start / End Page
588 / 597
Location
England
Related Subject Headings
- Patents as Topic
- Neoplasms
- Ipilimumab
- Immunotherapy
- Humans
- Drug Therapy, Combination
- Drug Industry
- Drug Evaluation, Preclinical
- Clinical Trials as Topic
- CTLA-4 Antigen
Citation
APA
Chicago
ICMJE
MLA
NLM
Morse, M. A. (2005). Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb. Curr Opin Mol Ther, 7(6), 588–597.
Morse, Michael A. “Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb.” Curr Opin Mol Ther 7, no. 6 (December 2005): 588–97.
Morse MA. Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb. Curr Opin Mol Ther. 2005 Dec;7(6):588–97.
Morse, Michael A. “Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb.” Curr Opin Mol Ther, vol. 7, no. 6, Dec. 2005, pp. 588–97.
Morse MA. Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb. Curr Opin Mol Ther. 2005 Dec;7(6):588–597.
Published In
Curr Opin Mol Ther
ISSN
1464-8431
Publication Date
December 2005
Volume
7
Issue
6
Start / End Page
588 / 597
Location
England
Related Subject Headings
- Patents as Topic
- Neoplasms
- Ipilimumab
- Immunotherapy
- Humans
- Drug Therapy, Combination
- Drug Industry
- Drug Evaluation, Preclinical
- Clinical Trials as Topic
- CTLA-4 Antigen